#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Extranodal marginal zone B-cell lymphoma (MALT type) Urethral valves Interstitial lung disease Aplastic anaemia Parkinson's disease Synovial sarcoma recurrent Philadelphia positive acute lymphocytic leukaemia Drug eruption Myelin oligodendrocyte glycoprotein antibody-associated disease Necrotising enterocolitis neonatal Severe myoclonic epilepsy of infancy Neuronal ceroid lipofuscinosis Colon cancer Arrhythmogenic right ventricular dysplasia Mucous membrane pemphigoid More trials…

    Learn about Rare Diseases

    Usher’s syndrome – Basic Information Arterial tortuosity syndrome – Treatment Antisynthetase syndrome – Basic Information Angelman’s syndrome – Life with Disease Adrenogenital syndrome Progressive multifocal leukoencephalopathy – Basic Information Aicardi-Goutieres syndrome – Trials in Disease Vascular malformation – Diagnostics Chondrosarcoma – Diagnostics Short-bowel syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Valganciclovir Salbutamol Sulfate Ubiquinol Cx-037231 Concizumab Lithium Carbonate POTASSIUM CLAVULANATE Clazakizumab Dexchlorpheniramine Maleate Pyridoxine Golodirsen Redasemtide GSKVX000000034795 Tumour Detection Apg777 Ht-29-A Prasugrel Hydrobromide ORX750 Dasatinib Bexotegrast More therapies…

    Learn about Your Condition

    Complicated appendicitis Cholangiocarcinoma Oesophageal atresia Brain abscess Osteosarcoma recurrent Acute lymphocytic leukaemia Abortion threatened Peripheral artery angioplasty Pleural mesothelioma Implantation complication Acquired haemophilia Noninfective chorioretinitis Transferrin decreased Organ donor Dementia with Lewy bodies More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Paoli-Calmettes Cancer Centre

Institut Paoli-Calmettes Cancer Centre

2co Bnzxvuuqp Di Sfeqss Moaeascqtlj Bi 1qro Mhloxrygvo 1zgtom Fkjubx

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Atezolizumab and Resiquimod Sulfate with Radiotherapy for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Resiquimod Sulfate
    • Atezolizumab
    France

  • Study of JDQ443, TNO155, and Tislelizumab for Patients with Advanced Solid Tumors with KRAS G12C Mutation

    Not recruiting

    2 1 1
    Investigated Drugs:
    • 1-{6-[(4M)-4-(5-Chloro-6-Methyl-1H -Indazol-4-Yl)-5-Methyl-3-(1-Methyl-1H -Indazol-5-Yl)-1H -Pyrazol-1-Yl]-2-Azaspiro[3.3]Heptan-2-Yl}Prop-2-En-1-One
    • Batoprotafib
    • Tislelizumab
    Belgium Denmark France Germany Italy The Netherlands +1

  • Study of IMGN632, Venetoclax, and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Pivekimab Sunirine
    • Azacitidine
    • Venetoclax
    France Germany Italy Spain

  • Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Capecitabine
    • Paclitaxel
    • Paclitaxel Albumin-Bound
    Austria Belgium Denmark France Germany Hungary +6

  • Study Comparing Ripretinib and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors Previously Treated with Imatinib

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastrointestinal stromal tumour
    Investigated Drugs:
    • Ripretinib
    • Sunitinib
    France Italy The Netherlands Norway Spain

  • Study of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Peritoneal cancer index
    • Fallopian tube cancer
    • Ovarian cancer
    Investigated Drugs:
    • Nemvaleukin Alfa
    • Topotecan Hydrochloride
    • Doxorubicin Hydrochloride
    Austria Belgium Czechia Denmark France Germany +4

  • Study of NP137 with carboplatin, paclitaxel and pembrolizumab combination therapy for patients with advanced endometrial or cervical cancer who had prior chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Cervix carcinoma
    • Endometrial cancer
    Investigated Drugs:
    • Human Monoclonal Igg1 Antibody Against Netrin-1
    • Carboplatin
    • Paclitaxel
    France

  • Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Leuprorelin Acetate
    • Abemaciclib
    • Anastrozole
    Austria Belgium Bulgaria France Germany Hungary +6

  • Study on Hormonal Treatment with Leuprorelin Acetate for Prostate Cancer Patients at High Risk of Recurrence After Surgery

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Leuprorelin Acetate
    France

  • Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Avelumab
    • Carboplatin
    • Cisplatin
    Austria Belgium Bulgaria Czechia Denmark France +12
Previous Page
1 … 26 27 28 29 30 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!